Thyroid Cancer
943 clinical trials
138 cell line models
15 approved drugs
Thyroid Cancer
Molecular Synopsis
Drugs and clinical candidates

15 drugs have received FDA approval for Thyroid Cancer:

  • Axicabtagene Ciloleucel
  • Cabozantinib-S-Malate
  • Dabrafenib
  • Doxorubicin Hydrochloride

219 drugs have a clinical trial registered for Thyroid Cancer.

407 compounds have been tested in Thyroid Cancer (324 <= 500nM potency).

Sources:,, ChEMBL.

Clinical trials
There are 943 clinical trials for Thyroid Cancer, 595 of which have one or more drug interventions, 348 with no drug intervention.
Cell line models

There are 138 Cell Line Models for Thyroid Cancer.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from mesh condition terms to Thyroid Cancer:
  • Adenocarcinoma, Follicular
  • Parathyroid Neoplasms
  • Thyroid Neoplasms
  • Thyroid Cancer, Papillary
  • Thyroid Carcinoma, Anaplastic
The following terms have been mapped from to Thyroid Cancer:
  • Non-Hodgkin lymphoma (NHL) that has recurred (come back). It is used in patients who have already received at least two systemic treatments. It is used in the following types of NHL--Follicular B-cell non-Hodgkin lymphoma
  • Follicular lymphoma that has relapsed. It is used in adults who have received at least two other systemic treatments
  • B-cell non-Hodgkin lymphoma (NHL) that is CD20 positive.It is used alone in patients with follicular lymphoma or low-grade lymphoma that has relapsed or is refractory (doesn??????t respond to treatment)
  • DLBCL in patients who had follicular lymphoma
  • Anaplastic thyroid cancer in patients whose disease is locally advanced or has metastasized (spread to other parts of the body) and who cannot receive local treatment. It is used with trametinib